Details for New Drug Application (NDA): 205122
✉ Email this page to a colleague
The generic ingredient in QUDEXY XR is topiramate. There are twenty-six drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the topiramate profile page.
Summary for 205122
Tradename: | QUDEXY XR |
Applicant: | Upsher Smith Labs |
Ingredient: | topiramate |
Patents: | 5 |
Pharmacology for NDA: 205122
Mechanism of Action | Cytochrome P450 2C19 Inhibitors Cytochrome P450 3A4 Inducers |
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Suppliers and Packaging for NDA: 205122
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
QUDEXY XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 205122 | NDA | Upsher-Smith Laboratories, LLC | 0245-1071 | 0245-1071-30 | 1 BOTTLE in 1 CARTON (0245-1071-30) / 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE |
QUDEXY XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 205122 | NDA | Upsher-Smith Laboratories, LLC | 0245-1071 | 0245-1071-90 | 1 BOTTLE in 1 CARTON (0245-1071-90) / 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 25MG | ||||
Approval Date: | Mar 11, 2014 | TE: | AB2 | RLD: | Yes | ||||
Patent: | 10,363,224 | Patent Expiration: | Mar 19, 2033 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF SEIZURES | ||||||||
Patent: | 8,652,527 | Patent Expiration: | Mar 19, 2033 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | 8,889,190 | Patent Expiration: | Mar 19, 2033 | Product Flag? | Y | Substance Flag? | Delist Request? |
Complete Access Available with Subscription